1
|
Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. An inventory of adjuvants used for vaccination in horses: the past, the present and the future. Vet Res 2023; 54:18. [PMID: 36864517 PMCID: PMC9983233 DOI: 10.1186/s13567-023-01151-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Accepted: 01/27/2023] [Indexed: 03/04/2023] Open
Abstract
Vaccination is one of the most widely used strategies to protect horses against pathogens. However, available equine vaccines often have limitations, as they do not always provide effective, long-term protection and booster injections are often required. In addition, research efforts are needed to develop effective vaccines against emerging equine pathogens. In this review, we provide an inventory of approved adjuvants for equine vaccines worldwide, and discuss their composition and mode of action when available. A wide range of adjuvants are used in marketed vaccines for horses, the main families being aluminium salts, emulsions, polymers, saponins and ISCOMs. We also present veterinary adjuvants that are already used for vaccination in other species and are currently evaluated in horses to improve equine vaccination and to meet the expected level of protection against pathogens in the equine industry. Finally, we discuss new adjuvants such as liposomes, polylactic acid polymers, inulin, poly-ε-caprolactone nanoparticles and co-polymers that are in development. Our objective is to help professionals in the horse industry understand the composition of marketed equine vaccines in a context of mistrust towards vaccines. Besides, this review provides researchers with a list of adjuvants, either approved or at least evaluated in horses, that could be used either alone or in combination to develop new vaccines.
Collapse
Affiliation(s)
- Flora Carnet
- grid.508204.bLABÉO, 14280 Saint-Contest, France ,grid.412043.00000 0001 2186 4076BIOTARGEN, Normandie University, UNICAEN, 14280 Saint-Contest, France
| | - Laure Perrin-Cocon
- grid.462394.e0000 0004 0450 6033CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Romain Paillot
- grid.451003.30000 0004 0387 5232School of Equine and Veterinary Physiotherapy, Writtle University College, Lordship Road, Writtle, Chelmsford, CM1 3RR UK
| | - Vincent Lotteau
- grid.462394.e0000 0004 0450 6033CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 21 Avenue Tony Garnier, 69007 Lyon, France
| | - Stéphane Pronost
- LABÉO, 14280, Saint-Contest, France. .,BIOTARGEN, Normandie University, UNICAEN, 14280, Saint-Contest, France.
| | - Pierre-Olivier Vidalain
- CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 21 Avenue Tony Garnier, 69007, Lyon, France.
| |
Collapse
|
2
|
French H, Segabinazzi L, Middlebrooks B, Peterson E, Schulman M, Roth R, Crampton M, Conan A, Marchi S, Gilbert T, Knobel D, Bertschinger H. Efficacy and Safety of Native and Recombinant Zona Pellucida Immunocontraceptive Vaccines Formulated with Non-Freund's Adjuvants in Donkeys. Vaccines (Basel) 2022; 10:1999. [PMID: 36560409 PMCID: PMC9788400 DOI: 10.3390/vaccines10121999] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2022] [Revised: 11/14/2022] [Accepted: 11/22/2022] [Indexed: 11/26/2022] Open
Abstract
This study aimed to test zona pellucida (ZP) vaccines’ immunocontraceptive efficacy and safety when formulated with non-Freund’s adjuvant (6% Pet Gel A and 500 Μg Poly(I:C)). Twenty-four jennies were randomly assigned to three treatment groups: reZP (n = 7) received three doses of recombinant ZP vaccine; pZP (n = 9) received two doses of native porcine ZP; and Control group (n = 8) received two injections of placebo. Jennies were monitored weekly via transrectal ultrasonography and blood sampling for serum progesterone profiles and anti-pZP antibody titres. In addition, adverse effects were inspected after vaccination. Thirty-five days after the last treatment, jacks were introduced to each group and rotated every 28 days. Vaccination with both pZP and reZP was associated with ovarian shutdown in 44% (4/9) and 71% (4/7) of jennies, 118 ± 33 and 91 ± 20 days after vaccination, respectively (p > 0.05). Vaccination delayed the chances of a jenny becoming pregnant (p = 0.0005; Control, 78 ± 31 days; pZP, 218 ± 69 days; reZP, 244 ± 104 days). Anti-pZP antibody titres were elevated in all vaccinated jennies compared to Control jennies (p < 0.05). In addition, only mild local injection site reactions were observed in the jennies after treatment. In conclusion, ZP vaccines formulated with non-Freund’s adjuvant effectively controlled reproduction in jennies with only minor localised side effects.
Collapse
Affiliation(s)
- Hilari French
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Lorenzo Segabinazzi
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Brittany Middlebrooks
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Erik Peterson
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Martin Schulman
- Veterinary Population Management Laboratory, Section of Reproduction, Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria 0002, South Africa
| | - Robyn Roth
- Council for Scientific and Industrial Research, Pretoria 0184, South Africa
| | - Michael Crampton
- Council for Scientific and Industrial Research, Pretoria 0184, South Africa
| | - Anne Conan
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Silvia Marchi
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Trevor Gilbert
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
| | - Darryn Knobel
- Department of Clinical Sciences, Ross University School of Veterinary Medicine, P.O. Box 334, Basseterre 00334, Saint Kitts and Nevis
- Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa
| | - Henk Bertschinger
- Veterinary Population Management Laboratory, Section of Reproduction, Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Pretoria 0002, South Africa
| |
Collapse
|
3
|
Guan LJ, Pei SX, Song JJ, Zhan PF, Han YN, Xue Y, Ding K, Zhao ZQ. Screening immune adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae. Front Vet Sci 2022; 9:922867. [PMID: 35958306 PMCID: PMC9360596 DOI: 10.3389/fvets.2022.922867] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Accepted: 07/05/2022] [Indexed: 11/29/2022] Open
Abstract
In this study, we screened adjuvants for an inactivated vaccine against Erysipelothrix rhusiopathiae (E. rhusiopathiae). Inactivated cells of E. rhusiopathiae strain HG-1 were prepared as the antigen in five adjuvanted inactivated vaccines, including a mineral-oil-adjuvanted vaccine (Oli vaccine), aluminum-hydroxide-gel-adjuvanted vaccine (Alh vaccine), ISA201-biphasic-oil-emulsion-adjuvanted vaccine (ISA201 vaccine), GEL02-water-soluble-polymer-adjuvanted vaccine (GEL vaccine), and IMS1313-water-soluble-nanoparticle-adjuvanted vaccine (IMS1313 vaccine). The safety test results of subcutaneous inoculation in mice showed that Oli vaccine had the most severe side effects, with a combined score of 35, followed by the ISA201 vaccine (25 points), Alh vaccine (20 points), GEL vaccine (10 points), and IMS1313 vaccine (10 points). A dose of 1.5LD50 of strain HG-1 was used to challenge the mice intraperitoneally, 14 days after their second immunization. The protective efficacy of Oli vaccine and Alh vaccine was 100% (8/8), whereas that of the other three adjuvanted vaccines was 88% (7/8). Challenge with 2.5LD50 of strain HG-1 resulted in a 100% survival rate, demonstrating the 100% protective efficacy of the Oli vaccine, followed by the GEL vaccine (71%, 5/7), IMS1313 vaccine (57%, 4/7), ISA201 vaccine (43%, 3/7), and Alh vaccine (29%, 2/7). Challenge with 4LD50 of strain HG-1 showed 100% (7/7) protective efficacy of the Oli vaccine and 71% (5/7) protective efficacy of the GEL vaccine, whereas the protective efficacy of other three adjuvanted vaccine was 14% (1/7). The Alh and GEL vaccines were selected for comparative tests in piglets, and both caused minor side effects. A second immunization with these two adjuvanted vaccines conferred 60 and 100% protective efficacy, respectively, after the piglets were challenged via an ear vein with 8LD100 of strain HG-1. After challenge with 16LD100 of strain HG-1, the Alh and GEL vaccines showed 40% and 100% protective efficacy, respectively. Our results suggested that GEL is the optimal adjuvant for an inactivated vaccine against E. rhusiopathiae.
Collapse
Affiliation(s)
- Li-Jun Guan
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
- College of Veterinary Medicine, Jilin University, Changchun, China
| | - Shi-Xuan Pei
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Ji-Jian Song
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Peng-Fei Zhan
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Yi-Nong Han
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Yun Xue
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Ke Ding
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
| | - Zhan-Qin Zhao
- Lab of Veterinary Microbiology, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, China
- *Correspondence: Zhan-Qin Zhao
| |
Collapse
|
4
|
Mathew MK, Virmani N, Bera BC, Anand T, Kumar R, Balena V, Sansanwal R, Pavulraj S, Sundaram K, Virmani M, Tripathi BN. Protective efficacy of inactivated reverse genetics based equine influenza vaccine candidate adjuvanted with Montanide TM Pet Gel in murine model. J Vet Med Sci 2019; 81:1753-1762. [PMID: 31656240 PMCID: PMC6943333 DOI: 10.1292/jvms.19-0399] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Equine influenza is a leading cause for respiratory illness in equines. Major control
measures involve vaccination which requires continuous harmonization owing to antigenic
drift. The present study focused on assessing the protective efficacy of an inactivated
recombinant equine influenza virus (rgEIV) vaccine candidate adjuvanted with
MontanideTM Pet Gel in murine model. The rgEIV was generated using reverse
genetics by incorporating HA and NA segments from EIV/H3N8, clade 2-Florida sublineage in
an A/WSN/33 /H1N1 backbone and inactivated by formalin. The vaccine was
prepared by mixing inactivated rgEIV with MontanideTM Pet Gel adjuvant followed
by intranasal inoculation into BALB/c mice intranasally. The immune responses and
protective efficacy of the vaccine was evaluated by measurement of antibody titer,
immunoglobulin subtyping, cytokines, clinical signs and pathological lesions after
immunization and challenge with wild EIV. Serology and cytokine expression pattern
indicated that the vaccine activated mixed Th1- and Th2-like responses of vaccine. Booster
immunization stimulated strong antibody responses (HAI titre: 192 ± 28.6) at 42 days post
immunization and the predominant antibody subtype was IgG1. Upregulation of interferon
(IFN)-gamma, interleukin (IL)-12 and
IL-2 levels indicates effective induction of Th1 type response. We
found that vaccination has protected mice against equine influenza virus challenge as
adjudged through a lack of nonappearance of visible clinical signs of disease, no loss of
body weight loss, reduced pathology in the lungs and markedly reduced virus shedding from
the respiratory tract. Therefore, we conclude that recombinant EIV vaccine candidate
adjuvanted with MontanideTM Pet Gel could aid in quick harmonization of the
vaccines through replacement of HA and NA genes for control of EIV outbreaks.
Collapse
Affiliation(s)
- Manu Kurian Mathew
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Nitin Virmani
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Bidhan Chandra Bera
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Taruna Anand
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Ramesh Kumar
- Lala Lajpat Rai University of Veterinary & Animal Sciences, Hisar-125004 Haryana, India
| | | | - Rekha Sansanwal
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Selvaraj Pavulraj
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Karthik Sundaram
- ICAR-National Research Centre on Equines, Sirsa Road, Hisar-125 001, Haryana, India
| | - Meenakshi Virmani
- Lala Lajpat Rai University of Veterinary & Animal Sciences, Hisar-125004 Haryana, India
| | | |
Collapse
|
5
|
Barros T, Moran G, Uberti B. Reactive Seizures After Vaccination in a Thoroughbred Broodmare. J Equine Vet Sci 2019. [DOI: 10.1016/j.jevs.2018.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
6
|
Nolan MB, Schulman ML, Botha AE, Human AM, Roth R, Crampton MC, Bertschinger HJ. Serum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund’s adjuvant in horses. Vaccine 2019; 37:1299-1306. [DOI: 10.1016/j.vaccine.2019.01.053] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 01/16/2019] [Accepted: 01/18/2019] [Indexed: 01/01/2023]
|
7
|
Rickettsia rickettsii Whole-Cell Antigens Offer Protection against Rocky Mountain Spotted Fever in the Canine Host. Infect Immun 2019; 87:IAI.00628-18. [PMID: 30396898 PMCID: PMC6346123 DOI: 10.1128/iai.00628-18] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2018] [Accepted: 10/30/2018] [Indexed: 01/24/2023] Open
Abstract
Rocky Mountain spotted fever (RMSF) is a potentially fatal tick-borne disease in people and dogs. RMSF is reported in the United States and several countries in North, Central, and South America. Rocky Mountain spotted fever (RMSF) is a potentially fatal tick-borne disease in people and dogs. RMSF is reported in the United States and several countries in North, Central, and South America. The causative agent of this disease, Rickettsia rickettsii, is transmitted by several species of ticks, including Dermacentor andersoni, Rhipicephalus sanguineus, and Amblyomma americanum. RMSF clinical signs generally include fever, headache, nausea, vomiting, muscle pain, lack of appetite, and rash. If untreated, it can quickly progress into a life-threatening illness in people and dogs, with high fatality rates ranging from 30 to 80%. While RMSF has been known for over a century, recent epidemiological data suggest that the numbers of documented cases and the fatality rates remain high in people, particularly during the last two decades in parts of North America. Currently, there are no vaccines available to prevent RMSF in either dogs or people. In this study, we investigated the efficacies of two experimental vaccines, a subunit vaccine containing two recombinant outer membrane proteins as recombinant antigens (RCA) and a whole-cell inactivated antigen vaccine (WCA), in conferring protection against virulent R. rickettsii infection challenge in a newly established canine model for RMSF. Dogs vaccinated with WCA were protected from RMSF, whereas those receiving RCA developed disease similar to that of nonvaccinated R. rickettsii-infected dogs. WCA also reduced the pathogen loads to nearly undetected levels in the blood, lungs, liver, spleen, and brain and induced bacterial antigen-specific immune responses. This study provides the first evidence of the protective ability of WCA against RMSF in dogs.
Collapse
|
8
|
Portuondo DL, Batista-Duharte A, Ferreira LS, de Andrade CR, Quinello C, Téllez-Martínez D, de Aguiar Loesch ML, Carlos IZ. Comparative efficacy and toxicity of two vaccine candidates against Sporothrix schenckii using either Montanide™ Pet Gel A or aluminum hydroxide adjuvants in mice. Vaccine 2017; 35:4430-4436. [PMID: 28687406 DOI: 10.1016/j.vaccine.2017.05.046] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 04/19/2017] [Accepted: 05/15/2017] [Indexed: 12/14/2022]
Abstract
Sporotrichosis is an important zoonosis in Brazil and the most frequent subcutaneous mycosis in Latin America, caused by different Sporothrix species. Currently, there is no effective vaccine available to prevent this disease. In this study, the efficacy and toxicity of the adjuvant Montanide™ Pet Gel A (PGA) formulated with S. schenckii cell wall proteins (ssCWP) was evaluated and compared with that of aluminum hydroxide (AH). Balb/c mice received two subcutaneous doses (1st and 14th days) of either the unadjuvanted or adjuvanted vaccine candidates. On the 21st day, anti-ssCWP antibody levels (ELISA), the phagocytic index, as well as the ex vivo release of IFN-γ, IL-4, and IL-17 by splenocytes and IL-12 by peritoneal macrophages were assessed. Cytotoxicity of the vaccine formulations was evaluated in vitro and by histopathological analysis of the inoculation site. Both adjuvanted vaccine formulations increased anti-ssCWP IgG, IgG1, IgG2a, and IgG3 levels, although IgG2a levels were higher in response to PGA+CWP100, probably contributing to the increase in S. schenckii yeast phagocytosis by macrophages in the opsonophagocytosis assay when using serum from PGA+CWP100-immunized mice. Immunization with AH+CWP100 led to a mixed Th1/Th2/Th17 ex vivo cytokine release profile, while PGA+CWP100 stimulated a preferential Th1/Th2 profile. Moreover, PGA+CWP100 was less cytotoxic in vitro, caused less local toxicity and led to a similar reduction in fungal load in the liver and spleen of S. schenckii- or S. brasiliensis-challenged mice as compared with AH+CWP100. These results suggest that PGA may be an effective and safe adjuvant for a future sporotrichosis vaccine.
Collapse
Affiliation(s)
- Deivys Leandro Portuondo
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Alexander Batista-Duharte
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Lucas Souza Ferreira
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Cleverton Roberto de Andrade
- São Paulo State University (UNESP), School of Dentistry, Department of Physiology & Pathology, Araraquara, SP, Brazil.
| | - Camila Quinello
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Damiana Téllez-Martínez
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Maria Luiza de Aguiar Loesch
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| | - Iracilda Zeppone Carlos
- São Paulo State University (UNESP), School of Pharmaceutical Sciences, Department of Clinical Analysis, Araraquara, SP, Brazil.
| |
Collapse
|
9
|
Trevisani MM, Hanna ES, Oliveira AF, Cardoso SA, Roque-Barreira MC, Soares SG. Vaccination of Mice with Virulence-Associated Protein G (VapG) Antigen Confers Partial Protection against Rhodococcus equi Infection through Induced Humoral Immunity. Front Microbiol 2017; 8:857. [PMID: 28553279 PMCID: PMC5425581 DOI: 10.3389/fmicb.2017.00857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2017] [Accepted: 04/27/2017] [Indexed: 11/13/2022] Open
Abstract
Rhodococcus equi is a facultative intracellular bacterium causing severe pyogranulomatous pneumonia, ulcerative enterocolitis, and mesenteric lymphadenopathy in foals aged less than 6 months. Less frequently, this pathogen affects various other species, such as pigs, cattle, cats, and even humans. Although rhodococcosis is treated with a combination of antimicrobial agents, resistance is developed in some cases, and thus, antimicrobial susceptibility must be monitored and managed. Considering these limitations of the current therapy and unavailability of a vaccine to prevent the disease, research is particularly focused on the development of an effective vaccine against rhodococcosis. Most vaccines undergoing development utilize the virulence-associated protein (Vap) A antigen, which was identified previously as a key virulence factor of R. equi. Nevertheless, other proteins, such as VapG, present in most virulent R. equi strains, are also encoded by vap genes located on the R. equi bacterial virulence plasmid. In the present study, we evaluated the effect of VapG immunization on the survival of R. equi-challenged mice. We used attenuated Salmonella as a carrier for VapG (Salmonella-vapG+), a procedure previously adopted to develop a VapA-based vaccine. We observed that vaccination with Salmonella-vapG+ induced both an increased IFN-γ, IL-12, and TNF-α production, and a decreased bacterial burden in organs of the R. equi-challenged mice. Nevertheless, Salmonella-vapG+ vaccination protected only 50% of the mice challenged with a lethal dose of R. equi. Interestingly, we observed an increased frequency of B cells in the spleen of Salmonella-vapG+-vaccinated mice and showed that Salmonella-vapG+-vaccinated R. equi-challenged B-cell-knockout mice did not reduce the bacterial burden. Given these results, we discussed the potential role of the humoral immune response induced by Salmonella-vapG+ vaccination in conferring protection against R. equi infection, as well as the employment of VapG antigen for obtaining hyperimmune plasma to prevent rhodoccocosis in young foals.
Collapse
Affiliation(s)
- Marcel M Trevisani
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| | - Ebert S Hanna
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| | - Aline F Oliveira
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| | - Silvia A Cardoso
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| | - Maria C Roque-Barreira
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| | - Sandro G Soares
- Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São PauloSão Paulo, Brazil
| |
Collapse
|
10
|
First comparison of adjuvant for trivalent inactivated Haemophilus parasuis serovars 4, 5 and 12 vaccines against Glässer's disease. Vet Immunol Immunopathol 2015; 168:153-8. [DOI: 10.1016/j.vetimm.2015.11.001] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2015] [Revised: 09/16/2015] [Accepted: 11/02/2015] [Indexed: 11/23/2022]
|